Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety and efficacy of Alrex (LE ophthalmic suspension, 0.2%)
versus Patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief
of the signs and symptoms of Seasonal Allergic Conjunctivitis (SAC).